Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.

Molecular basis of the VHL hereditary cancer syndrome

Kaelin, William G. · 2002 · Nature Reviews Cancer

Abstract

The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc885

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 146 references

Research works printed but not linked: 5

  1. Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
  2. Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
  3. Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
  4. Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
  5. Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).

Cited by

See all 865

Metadata

Authors
Kaelin, W. G.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Kaelin, William G.
Venue
Nature Reviews Cancer
Published
2002-09
Volume
2
Issue
9
Pages
673-682
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2093776019
Cited by
865
References
146
Citations by year
2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
FWCI
3.22
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Ear and Head Tumors
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
MeSH terms
Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular basis of the VHL hereditary cancer syndrome. https://app.cochat.ai/papers/10.1038/nrc885
The paper
Kaelin, W. G. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer. https://doi.org/10.1038/nrc885

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.